Clinical Trial Update: Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

This clinical trial update summarizes the safety and tolerability findings of an anti-IL-20 antibody in subjects with rheumatoid arthritis in a Phase 1 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Anti-IL-20 (anti-IL-20 antibody)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Rheumatoid Arthritis | Phase 1 | Status: COMPLETED